CLINICAL-LABORATORY AND PATHOPHYSIOLOGICAL CHANGES IN THE LIVER IN GOUT

Authors

  • Tursunova M.U. PhD, S enior Lecture Department of Internal Diseases No.2 and Endocrinology Tashkent State Medical University Author
  • Abdukhamidova Mubina Rustamovna (Master's Student) Scientific Supervisor: PhD, Author

Keywords:

gout, hyperuricemia, liver function tests, ALT, AST, GGT, alkaline phosphatase, non-alcoholic fatty liver disease, metabolic syndrome, xanthine oxidase, comorbidity.

Abstract

Gout is a chronic systemic metabolic disorder resulting from purine metabolism dysfunction, characterized by persistent hyperuricemia, monosodium urate crystal deposition in tissues, and recurrent arthritis episodes. Modern rheumatology and hepatology place significant emphasis on comorbid conditions in gout, notably non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). This paper comprehensively examines the pathogenetic interrelationships between hyperuricemia and hepatic parenchymal damage, specifically evaluating liver functional parameters, including cytolytic enzymes (ALT, AST), cholestatic markers (GGT, ALP), and synthetic/pigment functions. The correlation between serum uric acid levels, systemic inflammation severity, cytolysis markers, and liver steatosis grade is thoroughly analyzed. The absolute necessity of regular biochemical liver panel monitoring is highlighted to optimize urate-lowering and anti-inflammatory drug regimes while minimizing hepatotoxicity risk.

References

1.Nasonov E.L. Rheumatology: National Guide.—M.: GEOTAR-Media, 2020.—832 p.

2.Eliseev M.S. Gout and metabolic syndrome // Scientifically-Practical Rheumatology. — 2019. — Vol. 57, No. 2. — P. 207–214.

3.Korneeva N.V., Drapkina O.M. Liver condition in hyperuricemia and gout: modern concepts //Cardiovascular Therapy and Prevention.—2021.—Vol.20, No. 4.P. 28–35

4.Barskova V.G., Yakunina I.A. Comorbidity in gout: focus on non-alcoholic fatty liver disease // Modern Rheumatology. — 2018. — Vol. 12, No. 3. — P. 44–50.

5.Tursunova M.U., Abdukhamidova M.R. Evaluation of biochemical markers of cytolysis and cholestasis in purine metabolism disorders // Medical Journal of Uzbekistan. — 2024. — No. 2. — P. 15–21.

6.Richette P., Bardin T. Gout // Lancet. — 2010. — Vol. 375 (9711). — P. 318–328.

7.Dalbeth N., Merriman T.R., Stamp L.K. Gout // Lancet. — 2016. — Vol. 388 (10055). — P. 2039–2052.

8.Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey // Arthritis Rheum. — 2007. — Vol. 57 (1). — P. 109–115.

9.Xu C., Yu C., Xu L. et al. Association between serum uric acid level and non-alcoholic fatty liver disease: a community-based study // J Gastroenterol Hepatol. — 2010. — Vol. 25 (4). — P. 746–750.

10.Lanaspa M.A., Sanchez-Lozada L.G., Cicerchi C. et al. Uric acid stimulates fructokinase expression and secondary lipogenesis in the liver // PLoS One. — 2012. — Vol. 7 (2). — e32698.

Downloads

Published

2026-09-13